sequanamedical

Innovators in the management of fluid overload

liver disease – malignant ascites – heart failure

Investor presentation – May 2020

Disclaimers

Important Notice

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Sequana Medical NV (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation:

- This presentation has been prepared by the management of the Company. It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company and the nature of its securities before taking any investment decision with respect to securities of the Company. This presentation is not a prospectus or offering memorandum.
- The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation or undertaking to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.
- The presentation also contains information from third parties. Third party industry publications, studies and surveys may also contain that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company, or any of their respective parent or subsidiary undertakings or affiliates, or any of their respective directors, officers, employees, advisers or agents have independently verified the data contained therein. Thus, while the information from third parties has been accurately reproduced with no omissions that would render it misleading, and the Company believes it to be reliable, the Company cannot guarantee its accuracy or completeness. In addition, certain of the industry and market data contained in this presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this presentation.
- This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.
- This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.
- The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.
- By attending the meeting where this presentation is presented or by accepting a copy of it, you agree to be bound by the foregoing limitations.

Regulatory disclaimers:

- The **alfa**pump® has not yet received regulatory approval in the US and Canada. Any statement in this presentation about safety and efficacy of the **alfa**pump does not apply to the US and Canada because the device is currently undergoing clinical investigation in these territories.
- Sequana Medical's proprietary DSR therapy is under development and Sequana Medical is developing **alfa**pump DSR (Direct Sodium Removal) to deliver a convenient and fully implanted system for DSR therapy. DSR therapy and **alfa**pump DSR are still in development and it should be noted that any statements in this presentation regarding safety and efficacy arise from pre-clinical and clinical studies and ongoing clinical investigations which have yet to be completed. There is no link between DSR therapy, **alfa**pump DSR and ongoing investigations with the **alfa**pump system in Europe, the US and Canada.

COVID-19 notice

Sequana Medical is closely following the evolution of the COVID-19 global health crisis and is in **constant dialogue with its partners** to assess the impact and adapt its operations as necessary.

Although it is difficult to draw conclusions at this point on the systemic risk this disease could pose, the Company has put in place **mitigation plans to minimise delays**.

The impact of increased demands on the healthcare systems, restrictions on non-essential hospital visits and procedures, social-distancing and travel restrictions are expected to **result in delays to execution of clinical studies and impact sales**.

Sequana Medical will **update its guidance** on the expected impact and any material change in the Company's **operations and outlook when the situation is clarified**.

Company Overview

- Founded in 2006
- Gent, Belgium (HQ): corporate, clinical, commercial
- Zurich, Switzerland: manufacturing, engineering, QA/RA
- ~45 employees
- Euronext Brussels: SEQUA

alfapump® platform

Using the bladder to manage fluid overload

- Fully implanted
- Automatic operation
- Wireless battery charging
- Settings wirelessly adjusted
- Remote data monitoring



- Easy implantation
- Long-term implantation & catheter patency
- Moves up to 4 litres / day
- Virtually non-clogging
- No significant heating during charging and operation

Strong IP barriers through extensive patent portfolio & know-how

One platform – two products

alfapump®

Liver Disease (NASH)

Proven step change in liver refractory ascites and malignant ascites

Over 750 devices implanted

~145 K

patients / year with refractory ascites due to NASH within next 10-20y(1)

> €3 Bn / year
market opportunity

alfapump® DSR

Heart Failure

Breakthrough approach to fluid overload in heart failure

Clinical proof-of-concept of Direct Sodium Removal (DSR)

~400 K

patients / year hospitalised for volume overload due to heart failure by 2026(2)

> €5 Bn / year
market opportunity

Built upon proven European clinical & commercial experience

Source 1: Management estimate that is inclusive of estimated growth in prevalence of NASH for the US based on GlobalData Epidemiology Forecast to 2026
Source 2: Management estimate based on GlobalData Heart Failure Epidemiology Forecast to 2026; Costanzo et al. (2007). Kiglore et al (2017)

NASH drives US market attractiveness

Stronger competitive position in a much larger and dynamic market

alfapump® market potential	~€0.4 Bn / year	**>€3 Bn / year**
Underlying disease	Alcoholic Liver Disease, Hepatitis	**NASH**
Patient characteristic	“Outside mainstream”	**“Mainstream”**
Average age	40-50 yr	**70 yr+**
alfapump competitive positioning	✓	✓✓

Notes: current estimated EU Liver market: Data from 1980-2010, death rates between 9-12.4 per 100,000; Mokdad et al., 2014, Management estimates of 7.5% cirrhosis patients that die per year based on experts feedback.
forecast US Liver market: Management estimate that is inclusive of estimated growth in prevalence of NASH for the US based on GlobalData Epidemiology Forecast to 2026.

alfapump®

Proven step change in the management of liver refractory ascites and malignant ascites

sequanamedical

Liver cirrhosis and refractory ascites

A key complication of liver cirrhosis, with a dramatic impact on quality of life

Viral infections (Hepatitis B & C)

Alcoholic Liver Disease

Non-Alcoholic Steatohepatitis (NASH)





Typical patient life[4]

US forecast



Note : Prevalence of NASH in US is expected to increase by 63% between 2015-2030; Estes et al., 2018

Source 1 Management estimate in US based on Estes et al; GlobalData Nash Epidemiology Forecast to 2026; Noureddin et al., 2013
Source 2: Runyon 2009: approximately 50% of cirrhotic patients develop ascites within 10 years of diagnosis of cirrhosis
Source 3: Ginès et al., NEJM 2004: refractory ascites occurs in 5-10% patients with ascites
Source 4: Presentation of Dr. Rajiv Jalan at EASL in 2018, Large Volume Paracentesis (LVP) treatment cycle for refractory ascites

Cancer and malignant ascites

Severe complication of late-stage cancers

Fluid accumulation in the abdomen due to **drainage of lymph system**

Breast and ovarian cancer have longest survival with ascites(1)

Severe impact on **quality of life**

Reduces ability to undergo **anti-cancer treatment**



Malignant ascites due to breast and ovarian cancer(2):

EU5: ~18K

US: ~16K



Clear unmet need for improving Quality of Life and the ability to increase cancer treatment intensity

Source 1: Ayantunde & S. L. Parsons. Annals of Oncology 2007
Source 2: Management estimate based on WHO cancer incidence rates (2018) and Ayantunde & S. L. Parsons. Annals of Oncology 2007.

Severe limitations of existing therapies

Large Volume Paracentesis ("drainage")



Dramatically reduces quality of life

Transjugular Intrahepatic Portosystemic Shunt (TIPS)



Increases risk of hepatic encephalopathy above age of 65

(typical age of NASH ascites patients)

Liver transplant

Limited availability and high costs

alfapump® for long-term treatment

Over 750 implants and hundreds of years of patient experience

DirectLink Technology



Breakthrough Device Designation

Strong clinical validation

Clear increase in clinical outcomes

Sequana Medical data

Drastically reduced need for drainage



Results RCT study

Improved quality of life



Results RCT study

** p<0.05*

Improved nutrition



Results RCT study

RCT: Randomised Controlled Trial (2013-2016)

Strong health economics rationale

Significant reduction in regular drainage leads to:

- Reduced burden of disease
- Improved patient QoL
- Cost savings for hospitals and payers



LVP: Large Volume Paracentesis; QoL: Quality of Life

North American Pivotal Study (POSEIDON) underway

- Up to **50 patients** with recurrent or refractory ascites due to liver cirrhosis implanted with the **alfa**pump(1)
- Primary endpoint at **9 months after enrollment**:

  ⇨ proportion of patients with a 50% reduction in average number of paracentesis per month post-implant vs pre-implant



Note 1: in Study Cohort

alfapump® US approval roadmap

Key anticipated milestones



*Final CMS rule on reimbursement for breakthrough devices (NTAP) expected to further support reimbursement for the **alfa**pump*

*Note: timings presented in this slide reflect pre-COVID-19 expectations and are likely to be delayed given the current global health crisis

FDA: Food and Drug Administration (US); IDE: Investigational Device Exemption; NTAP: New Technology Add-on Payment

Self-commercialisation in US through specialty salesforce



Initial focus on key transplant centres

~50 person team:

35 sales reps, 10 clinical, 5 corporate

Focused European commercial activities

Building real world clinical experience and awareness



14 person team

Focus on specialist centers

Raise awareness at community hospital level

Current reimbursement:

- ✓ **Switzerland:** DRG
- ✓ **Germany:** DRG (NUB program(1))
- ✓ **UK:** local reimbursement – NICE guidance "use with special arrangements"

Note 1 NUB: "Neue Untersuchungs- und Behandlungsmethode" = add-on payment to DRG for new diagnostic and treatment methods

Strong support from patients and KOLs

Creating awareness amongst key stakeholders

Patients

“My lifestyle has changed 100%. I was able to sleep better, eat better […] making me feel that much better.

Family

“I’ve got my freedom back. I can go shopping without having to be worried. It’s amazing, he’s actually dancing with me again.

Clinicians

“The **alfa**pump is an exciting new technique. Patient doesn’t need to go to the hospital so often. It allows for the patient to be free, mobile and self-caring.

Building clinical evidence

Received: 22 March 2017 | First decision: 17 April 2017 | Accepted: 30 August 2017
DOI: 10.1111/apt.14331

WILEY APT Alimentary Pharmacology & Therapeutics

Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis

G. Stirnimann[1] | T. Berg[2] | L. Spahr[3] | S. Zeuzem[4] | S. McPherson[5] | F. Lammert[6] | F. Storni[1] | V. Banz[1] | J. Babatz[7] | V. Vargas[8] | A. Geier[9] | A. Stallmach[10] | C. Engelmann[2] | C. Trepte[11] | J. Capel[11] | A. De Gottardi[1]

AASLD AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

Improvement in Quality of Life and Reduction in Large Volume Paracentesis Requirement from the MOSAIC Study: a Multicenter, Open-Label, Prospective 3-Month Study of the ALFApump System in Refractory Ascites

Targeting patients through print & social media

alfapump® DSR

Breakthrough approach to
volume overload in heart failure
built on proven **alfa**pump platform

sequanamedical

Volume overload in heart failure – major clinical problem and key driver of costs



Excess sodium drives fluid overload

US hospitalisations annually due to HF[3]



HF – hospitalisations due to volume overload[3]

Typical hospital stay[4]

Annual costs of US HF-related hospitalisations[4]

- *40% of heart failure patients on IV loop diuretics have a poor response[1]*
- *24% re-admission rate at 30 days[2]*

Source 1: Testani, Circ Heart Failure, 2014 & 2016; Source 2: Ross et al. (2010); Source 3: Costanzo et al., J. Am. Coll., 2007; Source 4: Kilgore et al. (2017)

Direct sodium removal (DSR)

Remove the sodium and the body will eliminate the excess fluid



- Administer infusate to peritoneal cavity
- Infusate extracts sodium from the body
- alfapump® removes extracted sodium from peritoneal cavity via bladder
- Body restores balance by eliminating excess fluid

DSR pre-clinical and clinical Proof-of-Concept

Pre-clinical studies[1]



1: administration of 1 litre DSR infusate, with 2 hour dwell

** Weekly recommended intake for humans equals 14 grams (www.cdc.gov)*

First-in-human study[2] (N=10)



2: Cross-over study: administration of 1 litre DSR infusate (D10) vs. standard PD solution, with 2 hour dwell


Circulation

First in Human Experience with Peritoneal Direct Sodium Removal Using a Zero Sodium Solution: A New Candidate Therapy for Volume Overload

Veena S. Rao, Jeffrey M. Turner, Matthew Griffin, Devin Mahoney, Jennifer Asher, Sangchoon Jeon, Peter S. Yoo, Nabil Boutagy, Attila Feher, Albert Sinusas, F. Perry Wilson, ... **Show all Authors**

Originally published 8 Jan 2020 | https://doi.org/10.1161/CIRCULATIONAHA.119.043062 | Circulation. ;0:null

DSR therapy is capable of removing large quantities of sodium in a safe, tolerable and consistent manner

alfapump® DSR

Fully implanted and convenient system for DSR therapy leveraging proven elements



- ✓ DSR
- ✓ alfapump
- ✓ Implanted port

Potential chronic therapy for heart failure patients that are not well controlled on diuretics

RED DESERT – Repeated dose alfapump® DSR study for treatment of diuretic-resistant heart failure patients

- Up to **10 patients** with heart failure on high dose diuretics across two centres (Belgium and Georgia)
- Primary **safety** endpoint: absence/rate of device, procedure and/or therapy related serious adverse events
- Secondary **feasibility** endpoint: ability of **alfa**pump DSR to maintain a neutral sodium balance and maintain euvolemia
- Exploratory endpoint: impact of DSR to **restore response to diuretics**



Leading experts as Heart Failure Scientific Advisors

Dr. Maria Rosa Costanzo

Medical Director of the Edward Center for Advanced Heart Failure
Medical Director Heart Failure Research for the Advocate Heart Institute

Dr. Wilson Tang

Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University

Dr. Javed Butler

Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center

Dr. Jeffrey Testani

Associate Professor of Medicine and Director of Heart Failure Research at Yale University School of Medicine

alfapump® DSR development overview



*Note: study design and timings presented in this slide reflect pre-COVID-19 expectations and are likely to be delayed given the current global health crisis

Conclusion

Experienced **leadership team**

Value creation in the short term

sequanamedical

Strong organisation

Highly experienced leadership team supported by committed and well-reputed shareholders

Executive team:

Ian Crosbie
Chief Executive Officer

Kirsten Van Bockstaele
Chief Financial Officer

Oliver Goëdje
Chief Medical Officer

Martijn Blom
Chief Commercial Officer

Gijs Klarenbeek
Senior Medical Advisor

Dirk Fengels
VP Engineering & Manufacturing

Timur Resch
Global VP QM/QA/RA

Board of Directors:

Pierre Chauvineau
Board Chairman

Ian Crosbie
Chief Executive Officer

Wim Ottevaere
Director

Jason Hannon
Director

Rudy Dekeyser
Director

Erik Amble
Director

Expected near-term value drivers*

H1 2020

- **Initial results of RED DESERT study in heart failure patients with volume overload**
- **Completion of enrolment of POSEIDON study in recurrent and refractory liver ascites patients**
- Initiation of Prospective Malignant Ascites Study (ProMAS)
- Initiation of Step Counter study in refractory liver ascites patients

H2 2020

- **Presentation of results of RED DESERT study in heart failure patients with volume overload**
- **Interim results of POSEIDON study in recurrent and refractory liver ascites patients**
- Completion of enrolment of ProMAS study in patients with malignant ascites
- Initiation of **alfa**pump DSR feasibility study in patients with volume overload due to heart failure

**Note: These timings are likely to be delayed given the current global health crisis. Updated guidance will be provided when the situation is clarified.*

Back-up

Shareholders base and financial overview

Ticker: SEQUA – Euronext Brussels

- Outstanding shares: 15.8M
- Outstanding share options & warrants: 1.9M authorised of which 0.9M granted



- Analysts:
  - KBC Securities – Sandra Cauwenberghs & Lenny Van Steenhuyse
  - Kempen – Ingrid Gafanhão
  - Kepler Cheuvreux – Matthias Maenhaut & Kris Kippers
  - Mirabaud – Daniel Jelovcan
- Cash (31 December 2019): €5.6M
- Equity financing (22 January 2020): €19.0 M
- Financial calendar
  - Half year results 2020: 3 September 2020

DSR pre-clinical Proof-of-Concept

Clinically relevant sodium and fluid removal

Clinically relevant removal of sodium



Effective fluid removal



Source 1: Weekly recommended intake for humans equals 14 grams (www.cdc.gov)

DSR first-in-human study met primary and secondary endpoints

- ✓ DSR therapy was safe & well-tolerated with no adverse events or significant discomfort
- ✓ Substantially higher sodium removal with DSR vs standard Peritoneal Dialysis (PD) solution
- ✓ Minimal inter-patient variability





Results presented at key Cardiac Conferences and published in Circulation

Note: Cross-over study: DSR infusate (D10) vs. standard PD solution; 1 litre infusate administration with 2 hour dwell

contact info

✉ IR@sequanamedical.com

✆ +32 498 053579

www.sequanamedical.com

sequanamedical